Attached files
| file | filename |
|---|---|
| S-1/A - AMENDMENT NO.2 TO FORM S-1 - ARATANA THERAPEUTICS, INC. | d599715ds1a.htm |
| EX-10.10 - EX-10.10 - ARATANA THERAPEUTICS, INC. | d599715dex1010.htm |
| EX-10.8(A) - EX-10.8(A) - ARATANA THERAPEUTICS, INC. | d599715dex108a.htm |
| EX-1.1 - EX-1.1 - ARATANA THERAPEUTICS, INC. | d599715dex11.htm |
| EX-23.2 - EX-23.2 - ARATANA THERAPEUTICS, INC. | d599715dex232.htm |
| EX-23.3 - EX-23.3 - ARATANA THERAPEUTICS, INC. | d599715dex233.htm |
| EX-5.1 - EX-5.1 - ARATANA THERAPEUTICS, INC. | d599715dex51.htm |
| EX-5.2 - EX-5.2 - ARATANA THERAPEUTICS, INC. | d599715dex52.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the use in this Amendment No. 2 to the Registration Statement on Form S-1 of Aratana Therapeutics, Inc. (a development stage enterprise) of our report dated March 20, 2013, except for the effect of the reverse stock split as described in Note 17, as to which the date is May 23, 2013, and except for the third and fourth paragraphs in Note 1, as to which the date is January 21, 2014, relating to the financial statements of Aratana Therapeutics, Inc. (a development stage enterprise), which appears in such Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
January 27, 2014